Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

TransThera Approved for US Trials of Heart Failure Treatment

publication date: Dec 17, 2019

TransThera Biosciences, a Nanjing biotech, was granted approval to start a US trial of its novel small molecule inhibitor of phosphodiesterase 9 (PDE 9) to treat chronic heart failure. The company says TT-00920 is a novel, highly potent and selective PDE9 inhibitor. By inhibiting PDE9, TransThera believes TT-00920 restores the cardio-protective mechanism that is dysfunctional in heart failure. In preclinical tests, it improved cardiac function and reversed the ventricular remodeling of heart failure. Founded in 2016, TransThera develops novel therapeutics for cancer, cardiovascular and inflammatory diseases. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital